Background
As a new PPI, ilaprazole is less affected by the CYP2C19 1 . Currently, there are scarce of researchs investigating the cost-effectiveness of ilaprazole compared to other PPIs in China.
Results
To evaluate the cost-effectiveness of 10mg ilaprazole once daily vs. 20 mg omeprazole once daily to treat newly diagnosed duodenal ulcer patients in China.
Methods
A decision tree model was constructed and the treatment impact was projected up to one year (Fig 1) . The model was based on 10,000 patients each in the ilaprazole and omeprazole arms and evaluated a population of duodenal ulcer (DU) patients in the Chinese setting. The CYP2C19 polymorphism distribution in the Chinese population, the respective cure rates in the CYP2C19 genotype subgroups, the impact of duodenal ulcer on utility, and drug related side effects data were obtained from literature. The total cost of medications were calculated to estimate treatment costs based on current drug retail prices in China. Expert survey was conducted when published data were not available to populate the model such as costs of the side effects. Probabilistic sensitivity analysis was performed to determine the robustness of the results.
Conclusion Objective
In DU patients, ilaprazole cost ¥4,653,900 more than omeprazole and resulted in 35 more QALYs, giving an ICER value of ¥132,056/QALY. In DU patients with the CYP2C19 hetEM genotype, ilaprazole cost ¥1,551,610 more than omeprazole with 27 QALYs gained, yielding an ICER of ¥57,810/QALY The WHO's recommended threshold for intervention cost-effectiveness is 3 times GDP per capita per QALY 4 . In this study, the ICER of ilaprazole versus omeprazole in all DU patients is less than 3 times of China's per capita GDP (2014), and thus is considered cost-effective according to the WHO recommendation. In the CYP2C19 hetEM genotype patients, the ICER is a little higher than 2014 per capita GDP of China 2 , again meeting the WHO recommendation for costeffectiveness. A probabilistic sensitivity analysis found that there is 97% probability that the ICER of ilaprazole versus omeprazole in general DU patients is lower than the costeffectiveness threshold. The cost-effectiveness analysis results demonstrate that ilaprazole would be considered cost-effective compared with omeprazole to treat newly diagnosed duodenal ulcer patients in China based on the WHO's recommended threshold for intervention costeffectiveness. When treating duodenal ulcer patients who are CYP2C19 subpopulation of heterogeneous extensive metabolizer, ilaprazole is highly cost-effective, compared with omeprazole. 
